https://pharminent.com/bms-wins-first-fda-approval-for-celmod-class-with-zenbexus-in-multiple-myeloma/ 2026-08-14T19:35:32Z Pharminent en BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma 2026-08-14T19:35:28Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-14-2026/ 2026-08-14T16:45:59Z Pharminent en Strategic News Watch • August 14, 2026 2026-08-14T16:45:56Z Blog https://pharminent.com/ptc-therapeutics-acquires-sangamos-fabry-disease-gene-therapy/ 2026-08-13T20:38:49Z Pharminent en PTC Therapeutics Acquires Sangamo's Fabry Disease Gene Therapy 2026-08-13T20:30:29Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-13-2026/ 2026-08-13T19:20:54Z Pharminent en Strategic News Watch • August 13, 2026 2026-08-13T18:34:45Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-august-12-2026/ 2026-08-13T17:42:04Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • August 12, 2026 2026-08-13T17:42:02Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-august-12-2026/ 2026-08-13T17:39:32Z Pharminent en Manufacturing Intelligence • Weekly Digest • August 12, 2026 2026-08-13T17:39:29Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-august-11-2026/ 2026-08-13T17:38:05Z Pharminent en Oncology Intelligence Digest • August 11, 2026 2026-08-13T17:38:03Z Blog https://pharminent.com/new-taiho-cullian-data-heats-up-lung-cancer-drug-battle/ 2026-08-14T19:37:17Z Pharminent en New Taiho, Cullian data heats up lung cancer drug battle 2026-08-13T16:05:00Z Blog https://pharminent.com/prior-authorization-metrics-provide-new-insights-into-insurer-practices-but-gaps-remain/ 2026-08-14T18:52:32Z Pharminent en Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain 2026-08-13T12:00:00Z Blog https://pharminent.com/eli-lilly-files-six-lawsuits-to-combat-illegal-retatrutide-black-market/ 2026-08-13T17:50:39Z Pharminent en Eli Lilly Files Six Lawsuits to Combat Illegal Retatrutide Black Market 2026-08-12T20:01:12Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-12-2026/ 2026-08-12T19:16:05Z Pharminent en Strategic News Watch • August 12, 2026 2026-08-12T19:16:01Z Blog https://pharminent.com/sentynl-bets-up-to-475m-in-licensing-deal-for-mereos-rare-lung-disease-asset/ 2026-08-14T18:50:37Z Pharminent en Sentynl bets up to $475M in licensing deal for Mereo's rare lung disease asset 2026-08-12T11:39:51Z Blog